Allergan, Inc. Product Pipeline Review 2015

Transcription

1 2015 Reference Code: GMDHC06889CDB Publication Date: MAR 2015 Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)

2 Table of Contents Table of Contents... 2 List of Tables... 6 List of Figures... 6 Allergan, Inc. Snapshot... 7 Allergan, Inc. Overview... 7 Key Information... 7 Key Facts... 7 Allergan, Inc. Research and Development Overview... 8 Key Therapeutic Areas... 8 Allergan, Inc. Pipeline Review Pipeline Products by Stage of Development Pipeline Products Monotherapy Pipeline Products Combination Treatment Modalities Pipeline Products Partnered Products Partnered Products/Combination Treatment Modalities Pipeline Products Out-Licensed Products Out-Licensed Products/Combination Treatment Modalities Allergan, Inc. Pipeline Products Glance Allergan, Inc. Late Stage Pipeline Products Filing rejected/withdrawn Products/Combination Treatment Modalities Phase III Products/Combination Treatment Modalities Allergan, Inc. Clinical Stage Pipeline Products Phase II Products/Combination Treatment Modalities Phase I Products/Combination Treatment Modalities Allergan, Inc. Early Stage Pipeline Products Preclinical Products/Combination Treatment Modalities Discovery Products/Combination Treatment Modalities Allergan, Inc. Drug Profiles dihydroergotamine mesylate Product Description Mechanism of Action R&D Progress Aczone X Product Description Mechanism of Action R&D Progress AGN Product Description Mechanism of Action R&D Progress bimatoprost Product Description Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)

3 Mechanism of Action R&D Progress bimatoprost SR Product Description Mechanism of Action R&D Progress cyclosporine Product Description Mechanism of Action R&D Progress desmopressin acetate Product Description Mechanism of Action R&D Progress onabotulinumtoxin A Product Description Mechanism of Action R&D Progress oxymetazoline hydrochloride Product Description Mechanism of Action R&D Progress (bimatoprost + brimonidine tartrate) Product Description Mechanism of Action R&D Progress abicipar pegol Product Description Mechanism of Action R&D Progress AGN Product Description Mechanism of Action R&D Progress beclomethasone dipropionate Product Description Mechanism of Action R&D Progress brimonidine tartrate implant Product Description Mechanism of Action R&D Progress lidocaine Product Description Page(3)

4 Mechanism of Action R&D Progress senrebotase Product Description Mechanism of Action R&D Progress AGN Product Description Mechanism of Action R&D Progress AGN Product Description Mechanism of Action R&D Progress Drug to Agonize D2/D3 Receptors for Parkinson's Disease Product Description Mechanism of Action R&D Progress Drug to Agonize GABA Receptor for Epilepsy Product Description Mechanism of Action R&D Progress Drug to Inhibit Tyrosine Kinase for AMD Product Description Mechanism of Action R&D Progress Small Molecule for Glaucoma Product Description Mechanism of Action R&D Progress Neurotoxin Program Product Description Mechanism of Action R&D Progress Allergan, Inc. Pipeline Analysis Allergan, Inc. Pipeline Products by Target Allergan, Inc. Pipeline Products by Route of Administration Allergan, Inc. Pipeline Products by Molecule Type Allergan, Inc. Pipeline Products by Mechanism of Action Allergan, Inc. Recent Pipeline Updates Allergan, Inc. Dormant Projects Allergan, Inc. Discontinued Pipeline Products Discontinued Pipeline Product Profiles budesonide Page(4)

5 dexamethasone memantine hydrochloride onabotulinumtoxin A Allergan, Inc. Company Statement Allergan, Inc. Locations And Subsidiaries Head Office Other Locations & Subsidiaries Allergan, Inc. - Key Manufacturing Facilities Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Disclaimer Page(5)

6 List of Tables Allergan, Inc., Key Information... 7 Allergan, Inc., Key Facts... 7 Allergan, Inc. Pipeline by Indication, Allergan, Inc. Pipeline by Stage of Development, Allergan, Inc. Monotherapy Products in Pipeline, Allergan, Inc. Combination Treatment Modalities in Pipeline, Allergan, Inc. Partnered Products in Pipeline, Allergan, Inc. Partnered Products/ Combination Treatment Modalities, Allergan, Inc. Out-Licensed Products in Pipeline, Allergan, Inc. Out-Licensed Products/ Combination Treatment Modalities, Allergan, Inc. Filing rejected/withdrawn, Allergan, Inc. Phase III, Allergan, Inc. Phase II, Allergan, Inc. Phase I, Allergan, Inc. Preclinical, Allergan, Inc. Discovery, Allergan, Inc. Pipeline by Target, Allergan, Inc. Pipeline by Route of Administration, Allergan, Inc. Pipeline by Molecule Type, Allergan, Inc. Pipeline Products by Mechanism of Action, Allergan, Inc. Recent Pipeline Updates, Allergan, Inc. Dormant Developmental Projects, Allergan, Inc. Discontinued Pipeline Products, Allergan, Inc., Subsidiaries Allergan, Inc., Key Manufacturing Facilities List of Figures Allergan, Inc. Pipeline by Top 10 Indication, Allergan, Inc. Pipeline by Stage of Development, Allergan, Inc. Monotherapy Products in Pipeline, Allergan, Inc. Partnered Products in Pipeline, Allergan, Inc. Pipeline by Top 10 Target, Allergan, Inc. Pipeline by Top 10 Route of Administration, Allergan, Inc. Pipeline by Top 10 Molecule Type, Allergan, Inc. Pipeline Products by Top 10 Mechanism of Action, Page(6)

7 Allergan, Inc. Snapshot Allergan, Inc. Overview Allergan, Inc. (Allergan) is a global healthcare company. It develops and commercializes novel pharmaceuticals, over-the-counter products, biologics and the medical devices addressing ophthalmic, neurological, medical aesthetic, medical dermatology, breast aesthetic, urological, and other specialty markets. The company s research and development efforts focus on products and technologies related to wide range of specialty areas with significant unmet clinical needs. The company sells its products through a network of own distributors and direct subsidiaries in approximately 40 countries and through independent distributors in about 100 countries across the world. Key Information Allergan, Inc., Key Information Web Address Turnover ($ Mn) Financial year-end: No. of Employees New York Stock Exchange Source: Global Markets Direct Key Facts Allergan, Inc., Key Facts Corporate Address Telephone Fax URL Ticker Symbol, Exchange No. of Employees Fiscal Year End Revenue (in USD Million) Industry Source: Global Markets Direct Global Markets Direct. This report is a licensed product and is not to be photocopied Page(7)

8 Allergan, Inc. Research and Development Overview Key Therapeutic Areas Allergan, Inc. has promising clinical drug candidates for 12 major therapeutic areas, Cardiovascular, Central Nervous System, Gastrointestinal, Male Health, Musculoskeletal, Respiratory, Immunology, Metabolic Disorders, Genito Urinary System And Sex Hormones, Ophthalmology, Dermatology and Undisclosed. Allergan, Inc. is focused on the development of compounds as these indications have a large market need and these compounds have the potential to offer new benefits to patients and will generate value creating partnerships with pharmaceutical companies. Cardiovascular Central Nervous System Dermatology Gastrointestinal Genito Urinary System And Sex Hormones Immunology Male Health Metabolic Disorders Musculoskeletal Ophthalmology Respiratory Undisclosed Page(8)

9 Allergan, Inc. Pipeline by Top 10 Indication, 2015 Source: Global Markets Direct Allergan, Inc. Pipeline by Indication, 2015 Therapy Area Indication Products/Combined Treatment Modalities Source: Global Markets Direct Page(9)

10 Allergan, Inc. Pipeline Review Pipeline Products by Stage of Development Allergan, Inc. Pipeline by Stage of Development, 2015 Source: Global Markets Direct Allergan, Inc. Pipeline by Stage of Development, 2015 Stage Development Products Source: Global Markets Direct Page(10)

11 Allergan, Inc. Drug Profiles dihydroergotamine mesylate Product Description Mechanism of Action R&D Progress Page(23)

12 Aczone X Product Description Mechanism of Action R&D Progress Page(24)

13 Appendix Appendix Methodology Global Markets Direct s dedicated Research and Analysis Teams consist of experienced professionals with a pedigree in marketing, market research, consulting background in the pharmaceutical industry and advanced statistical expertise. Global Markets Direct adheres to the Codes of Practice of the Market Research Society ( and the Strategic and Competitive Intelligence Professionals ( All Global Markets Direct databases are continuously updated and revised. The following research methodology is followed for all databases and reports. Coverage The objective of updating Global Markets Direct coverage is to ensure that it represents the most up to date vision of the industry possible The report covers all the pharmaceutical/biopharmaceutical products under development across the globe. The scope of the pipeline products coverage aims at setting up the boundaries of the project. It comprises all the therapeutic products that are in the course of development, however, if a drug is solely used for research purpose, where the intention for its further development as a drug is not clear or the strategy for commercialization is not known, the drug is not included in the report. Global Markets Direct aims to cover major news events and deals in the pharmaceutical industry, updated on daily basis. The coverage is further streamlined and strengthened with additional inputs from Global Markets Direct Expert Panel (see below). Secondary Research The research process begins with exhaustive secondary research on internal and external sources being carried out to source/update the pipeline products information. The secondary research sources that are typically referred to include, but are not limited to: Company websites, annual reports, financial reports, company pipeline chart, broker reports, investor presentations and SEC filings, journals and conferences, clinical trials registries, internal proprietary databases, news articles, press releases and web-casts specific to the companies operating in the respective indication/therapy area. Primary Research Global Markets Direct conducts hundreds of primary interviews a year with industry participants and commentators in order to validate its pipeline products data. A typical research interview provides first-hand information on the pipeline therapeutics landscape and helps in validating and strengthening the secondary research findings. Primary research involves interactions with the industry participants across geographies. The participants who typically take part in such a process include, but are not limited to: CEOs, VPs, business development managers, market intelligence managers and national sales managers. Expert Panel Validation Global Markets Direct uses a panel of experts to cross verify research methodologies, and drive its analytical content. The Global Markets Direct expert panel comprises senior research managers, marketing managers, product specialists & international sales managers. Disclaimer All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, Global Markets Direct. Global Markets Direct. This report is a licensed product and is not to be photocopied Page(80)